Abstract
Simple SummaryThe neurofibromatoses—neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis—are genetic tumor predisposition syndromes in which affected patients are at risk for the development of nerve-associated central and peripheral tumors. Patients often develop multiple tumors which can result in significant symptoms and morbidity. Treatment of the tumors associated with these disorders has evolved over the past decade, including significant work focused on inhibition of the signaling dysregulation and symptom minimization. This review outlines the most common tumor types associated with each of these syndromes and the current progress in therapeutic options.Over the past several years, management of the tumors associated with the neurofibromatoses has been recognized to often require approaches that are distinct from their spontaneous counterparts. Focus has shifted to therapy aimed at minimizing symptoms given the risks of persistent, multiple tumors and new tumor growth. In this review, we will highlight the translation of preclinical data to therapeutic trials for patients with neurofibromatosis, particularly neurofibromatosis type 1 and neurofibromatosis type 2. Successful inhibition of MEK for patients with neurofibromatosis type 1 and progressive optic pathway gliomas or plexiform neurofibromas has been a significant advancement in patient care. Similar success for the malignant NF1 tumors, such as high-grade gliomas and malignant peripheral nerve sheath tumors, has not yet been achieved; nor has significant progress been made for patients with either neurofibromatosis type 2 or schwannomatosis, although efforts are ongoing.
Highlights
Recent neurofibromatosis (NF)-focused clinical trials and consensus guidelines have highlighted the unique behavior and management needed for tumors which arise in this group of rare, genetic tumor predisposition syndromes
The neurofibromatoses are a group of three distinct genetic disorders which predispose one to the development of peripheral and central nervous system tumors and include neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis
We identify the most common tumors which arise in these patient populations and highlight recent therapeutic trials which leverage what is known about the aberrant cell signaling, for neurofibromatosis type 1 and neurofibromatosis type 2
Summary
Recent neurofibromatosis (NF)-focused clinical trials and consensus guidelines have highlighted the unique behavior and management needed for tumors which arise in this group of rare, genetic tumor predisposition syndromes. The neurofibromatoses are a group of three distinct genetic disorders which predispose one to the development of peripheral and central nervous system tumors and include neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Treatment of the tumors associated with these disorders has evolved over the past decade, including significant work focused on inhibition of the signaling dysregulation and symptom minimization. We identify the most common tumors which arise in these patient populations and highlight recent therapeutic trials which leverage what is known about the aberrant cell signaling, for neurofibromatosis type 1 and neurofibromatosis type 2
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.